|1.||Sullivan, Aideen M: 4 articles (10/2012 - 02/2004)|
|2.||Hurley, Fiona M: 2 articles (10/2012 - 02/2004)|
|3.||Costello, Daniel J: 2 articles (10/2012 - 02/2004)|
|4.||O'Keeffe, Gerard W: 2 articles (10/2012 - 09/2005)|
|5.||Pohl, Jens: 2 articles (04/2012 - 08/2008)|
|6.||Lin, Guiting: 2 articles (03/2009 - 08/2008)|
|7.||Bella, Anthony J: 2 articles (03/2009 - 08/2008)|
|8.||Lue, Tom F: 2 articles (03/2009 - 08/2008)|
|9.||Lin, Ching-Shwun: 2 articles (03/2009 - 08/2008)|
|10.||Yang, Yang: 1 article (01/2015)|
|1.||Parkinson Disease (Parkinson's Disease)
02/01/2004 - "This study shows that the delayed administration of a single dose of GDF-5 has significant protective effects on the damaged adult rat nigrostriatal pathway, reinforcing its therapeutic potential for Parkinson's disease."
10/01/2012 - "Growth/differentiation factor 5 (GDF5) is a neurotrophic factor that promotes the survival of midbrain dopaminergic neurons in vitro and in vivo and as such is potentially useful in the treatment of Parkinson's disease (PD). "
04/01/2012 - "Growth differentiation factor 5 (GDF5), in addition to its role in bone and joint development, protects dopaminergic (DA) neurons from degeneration, and is a potential therapeutic agent for Parkinson's disease. "
04/01/2012 - "The neurotrophin growth/differentiation factor 5 (GDF5) is studied as a potential therapeutic agent for Parkinson's disease as it is believed to play a role in the development and maintenance of the nigrostriatal system. "
09/01/2005 - "The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment."
08/01/2008 - "Intracavernous injection of low (0.4 microg) or intermediate-concentration GDF-5 (2 microg) was effective in preserving erectile function in a rat model of neurogenic erectile dysfunction. "
03/01/2009 - "Compromised CN function is a significant cause of erectile dysfunction development following prostatectomy and serves as the primary target for potential neuroprotective or regenerative strategies utilizing NGFs such as BDNF, GDF-5, and NTN, and/or targeted novel therapeutics modulating signaling pathways."
01/01/2004 - "The GDF-5 composites were effective in the necrosis model. "
01/01/2011 - "A genetic association study between growth differentiation factor 5 (GDF 5) polymorphism and knee osteoarthritis in Thai population."
01/01/2008 - "The growth differentiation factor 5 (GDF5) core promoter polymorphism is not associated with knee osteoarthritis in the Greek population."
02/01/2013 - "Although the +104T/C polymorphism in the 5' untranslated region (UTR) of growth differentiation factor 5 (GDF5) plays a role in the pathogenesis of knee osteoarthritis, the results have been inconsistent. "
|5.||Wounds and Injuries (Trauma)
|1.||Glial Cell Line-Derived Neurotrophic Factor (GDNF)
|2.||Bone Morphogenetic Protein 7
|5.||Bone Morphogenetic Protein Receptors
|6.||5' Untranslated Regions (5' UTR)
|7.||Brain-Derived Neurotrophic Factor (BDNF)
|8.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|9.||Transforming Growth Factor beta (TGF-beta)
|10.||von Willebrand Factor
|3.||Prostatectomy (Retropubic Prostatectomy)